慢性髓性白血病中新型酪氨酸激酶抑制剂的突变分析及克服伊马替尼耐药性 - Suppr

Suppr

超能文献

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.

作者信息

Mauro Michael J

机构信息

Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR 97239, USA.

出版信息

Curr Treat Options Oncol. 2007 Aug;8(4):287-95. doi: 10.1007/s11864-007-0036-y.

DOI:10.1007/s11864-007-0036-y

PMID:18157514

Abstract

摘要

相似文献

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.慢性髓性白血病中新型酪氨酸激酶抑制剂的突变分析及克服伊马替尼耐药性

Curr Treat Options Oncol. 2007 Aug;8(4):287-95. doi: 10.1007/s11864-007-0036-y.

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.来自印度的慢性髓性白血病患者中对伊马替尼疑似耐药的BCR-ABL激酶结构域突变谱——突变罕见且分布各异。

Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486.

3. Imatinib therapy in chronic myelogenous leukemia.3. 伊马替尼治疗慢性粒细胞白血病

Intern Med. 2007;46(2):95-7. doi: 10.2169/internalmedicine.46.1781. Epub 2007 Jan 15.

New tyrosine kinase inhibitors in chronic myeloid leukemia.慢性髓性白血病中的新型酪氨酸激酶抑制剂

Haematologica. 2005 Apr;90(4):534-41.

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.酪氨酸激酶抑制剂治疗慢性髓性白血病的进展：Bcr-Abl 突变和突变分析的作用不断演变。

Pharmacogenomics. 2012 Aug;13(11):1271-84. doi: 10.2217/pgs.12.103.

Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.波兰慢性髓性白血病患者接受伊马替尼治疗时BCR-ABL基因突变的频率：MAPTEST研究的最终报告

Pol Arch Med Wewn. 2009 Dec;119(12):789-94.

ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.ETV6-ABL1阳性“慢性髓性白血病”：对酪氨酸激酶抑制的临床和分子反应

Haematologica. 2011 Feb;96(2):342-3. doi: 10.3324/haematol.2010.036673. Epub 2010 Dec 29.

Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.慢性髓性白血病患者对伊马替尼（格列卫）反应的分子监测：沙特阿拉伯一家三级医疗医院的经验。

Genet Test Mol Biomarkers. 2010 Feb;14(1):67-74. doi: 10.1089/gtmb.2009.0126.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.对伊马替尼（STI571）治疗耐药的分子和染色体机制。

Leukemia. 2002 Nov;16(11):2190-6. doi: 10.1038/sj.leu.2402741.

Chronic myeloid leukemia: advances in diagnosis and management.慢性髓性白血病：诊断与管理的进展

JAAPA. 2013 Feb;26(2):26-9. doi: 10.1097/01720610-201302000-00005.

引用本文的文献

Chronic myeloid leukemia: mechanisms of resistance and treatment.慢性髓性白血病：耐药机制与治疗。

Hematol Oncol Clin North Am. 2011 Oct;25(5):981-95, v. doi: 10.1016/j.hoc.2011.09.004. Epub 2011 Oct 19.

本文引用的文献

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.尼罗替尼（原AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药和不耐受的慢性期费城染色体阳性慢性髓性白血病患者有效。

Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.达沙替尼或高剂量伊马替尼用于一线伊马替尼治疗失败后的慢性期慢性髓性白血病：一项随机2期试验。

Blood. 2007 Jun 15;109(12):5143-50. doi: 10.1182/blood-2006-11-056028. Epub 2007 Feb 22.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.接受伊马替尼治疗的慢性髓性白血病患者的五年随访

N Engl J Med. 2006 Dec 7;355(23):2408-17. doi: 10.1056/NEJMoa062867.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.达沙替尼在伊马替尼治疗失败后的慢性期慢性髓性白血病中可诱导显著的血液学和细胞遗传学反应。

Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.INNO-406是一种新型的BCR-ABL/Lyn双酪氨酸激酶抑制剂，可抑制中枢神经系统中Ph+白血病细胞的生长，而环孢素A可增强其体内活性。

Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.尼洛替尼用于伊马替尼耐药的慢性粒细胞白血病和费城染色体阳性的急性淋巴细胞白血病。

N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。

N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.慢性髓系白血病管理的不断演变的概念：代表欧洲白血病网的专家小组的建议

Blood. 2006 Sep 15;108(6):1809-20. doi: 10.1182/blood-2006-02-005686. Epub 2006 May 18.

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.有机阳离子转运体1（OCT-1）介导的内流是伊马替尼而非尼罗替尼（AMN107）细胞内摄取的关键决定因素：OCT-1活性降低是对伊马替尼体外敏感性低的原因。

Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.监测接受酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者：关于统一当前检测BCR-ABL转录本和激酶结构域突变方法以及结果表达的综述与建议。

Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验